/
Our First-in-class, breakthrough modifier gene therapy platform presents a potential paradigm shift in treating inherited retinal diseases and blindness diseases affecting millions across the globe. Our technology pipeline includes: Novel Modifier Gene Therapy Platform OCU400 - Based on the use of nuclear hormone receptors ("NHRs"), we believe our novel modifier gene therapy platform has the po…
$1.34
$0.02 (-1.47%)
Live · 06:15 PM
The business is unprofitable at the operating level (-1425.70% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 8.8%, steady but not accelerating. Margins contracted 75.3pp, which offsets some of the top-line progress.
ROIC dropped from -78.91% to -104.33%, capital efficiency is deteriorating. Negative free cash flow of -$57M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$4M
▲ +8.8% YoY
Net Income (TTM)
-$72M
▼ -25.5% YoY
Op. Margin
-1483.85%
▼ -75.3pp YoY
ROIC
-144.77%
▼ -25.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$60M
▼ -25.5% YoY
Op. Cash Flow (TTM)
-$59M
▼ -35.2% YoY
Net Debt
$1M
Cash & Equiv.
$32M
3Y CAGR: +21.0%
Continue Research
Ocugen (OCGN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Ocugen scores 30/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Ocugen scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,483.9% operating margin and a -144.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh OCGN's valuation and scores 30/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.